Company news
Island Pharmaceuticals Ltd (ASX:ILA) news
Island Pharmaceuticals Ltd news releases on 6ix. Latest, Oct 2, 2026: Galidesivir GMP manufacturing commences
Press releases & updates
Galidesivir GMP manufacturing commences
October 1, 2026
Pivotal Marburg data secured for Galidesivir FDA pathway
August 30, 2026
Island boosts Galidesivir supply as Ebola surges
August 20, 2026
Texas Biomed SOW accelerates pivotal FDA pathway
July 12, 2026
Investor Presentation - Ebola Clinical Program
July 7, 2026
Galidesivir approved for treatment use in in Ebola epidemic
July 6, 2026
Pause in Trading
July 2, 2026
Singapore Patent Expands Island's ISLA 101 Viral Protection
July 1, 2026
FDA Grants Orphan Designation for Galidesivir in Marburg
June 16, 2026
Investor Presentation - Asia Dengue Summit
June 15, 2026
Investor presentation
June 10, 2026
Island Secures USAMRIID Support for Galidesivir Study
June 9, 2026
Island Advances Galidesivir GMP Manufacturing for Biodefence
June 3, 2026
Island Adds Biodefence Leader as Filovirus Risks Escalate
May 20, 2026
Island Bolsters US Biodefence Readiness Ahead of Trials
May 18, 2026
Antiviral pipeline expansion through strategic collaboration
March 8, 2026
US Government collaboration for Galidesivir development
March 3, 2026
Trading Halt
March 1, 2026
Appendix 4D & Half-Year Financial Statements
February 25, 2026
Response to ASX Query Letter
February 10, 2026
$9m placement to advance US biodefence opportunity
February 3, 2026
FDA confirms Galidesivir approval pathway
February 3, 2026
Quarterly Appendix 4C and Activities Report
January 26, 2026
US Patent Granted for Galidesivir in filoviridae viruses
January 6, 2026
Ongoing engagement with the US FDA
January 4, 2026
Agreement with Texas Biomed for Galidesivir Program
December 16, 2025
Island expands Galidesivir IP with US Patent Grant
December 4, 2025
Additional FDA Submission completed for Galidesivir
December 3, 2025
Options exercised raises $1million
December 2, 2025
Coalition acceptance to advance US procurement & stockpiling
November 23, 2025
Island engages advisers to advance biodefence strategy
November 19, 2025
FDA agrees Animal Rule pathway and PRV eligibility
November 16, 2025
FDA confirms response timing for Galidesivir
October 21, 2025
US FDA Type C meeting briefing document submitted
September 28, 2025
FDA Meeting request granted
September 18, 2025
FDA meeting request lodged for Galidesivir
August 31, 2025
Preliminary Final Report
August 28, 2025
Options exercise from existing substantial shareholder
August 11, 2025
Completion of Galidesivir transaction
July 30, 2025
Portfolio expansion achieved with acquisition of Galidesivir
July 8, 2025
Successful Phase 2 clinical trial of ISLA-101
June 12, 2025
Island completes $3.6 million placement
May 20, 2025
Quarterly Activities & Cashflow Report
April 29, 2025
Phase 2a/b clinical trial update
April 22, 2025
Completion of patient dosing in Phase 2b clinical trial
February 11, 2025
Completion of enrolment in Phase 2b arm
January 21, 2025
ISLA-101 Phase 2b clinical trial enrols first subjects
January 7, 2025
US patent granted for ISLA-101
December 10, 2024
ISLA-101 shows anti-dengue activity in Phase 2a readout
November 26, 2024
Receipt of R&D tax refund for FY2024
November 21, 2024